Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s

Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.